NEW YORK, May 12, 2015 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a complaint has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities that purchased the securities of Aerie Pharmaceuticals Inc., (“Aerie” or the “Company”) (Nasdaq:AERI) between August 6, 2014 and April 23, 2015, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934.
The complaint alleges that, throughout the Class Period, Aerie and certain of its executive officers made a series of false and misleading statements and/or failed to disclose material adverse information about the future prospects for Rhopressa.
On April 23, 2015, Aerie issued a press release announcing the results of its first Phase 3 registration trial for Rhopressa. According to the press release, "[t]he trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily Rhopressa compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma."
On this news, shares of Aerie's stock fell $22.52 per share, or over 63 percent, to close on April 24, 2015 at $12.87 per share.
If you purchased Aerie securities during the Class Period, you may, no later than June 29, 2015, request that the Court appoint you lead plaintiff of the proposed class. A lead plaintiff is a representative party that acts on behalf of all class members in directing the litigation. Any member of the purported class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has over 35 attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at firstname.lastname@example.org, or visit our website at www.whafh.com. All e-mail correspondence should make reference to the “Aerie Pharmaceuticals Investigation.”
Attorney advertising. Prior results do not guarantee a similar outcome.
Wolf Haldenstein Adler Freeman & Herz LLP Patrick Donovan, Esq. Gregory Stone, Director of Case and Financial Analysis Email: email@example.com, firstname.lastname@example.org or email@example.com Tel: (800) 575-0735 or (212) 545-4774
Source:Wolf Haldenstein Adler Freeman & Herz LLP